^
    9ms
    @MartinTallman Hi sir We hv young patient with AML with 5q deletion with biallelic CEBPA How should I stratify this patient High risk or standard risk? Whether should go MSD Allo transplant upfront or MRD Based? Haplotransplan if NO MSD?? (@AmitBha11780231)
    Clinical
    |
    CEBPA (CCAAT Enhancer Binding Protein Alpha)
    9ms
    Check out the final version of the @UChicagoLeuk article on FLT3 inhibitors in pts with FLT3 N676K mutated AML! The effort was led by @RoloffGreg @michaelwd https://t.co/VLDjMBnnfH (@UChicagoLeuk)
    Clinical
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 N676K
    9ms
    Excellent MDS session chaired by @beatalleukemia featuring @MikkaelSekeres @DrPinkalDesai & others - the topics included clinical trial endpoints, HMA-exposed AML, CCUS, and IRAK4 inhibitors! #mdssm #DAVABermudaHeme (@Anand_88_Patel)
    Clinical
    |
    IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    9ms
    @TheEBMT @EHA_Hematology Hot topic FLT3 mutated AML FLT3: - Transmembrane TK - Gene mapped on Chr. 13 - Normally expressed by hematopoietic stem, but not in mature cells - Promoting cell survival, proliferation, and differentiation (@HematoUptodate)
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    9ms
    Great MDS/AML therapy session chaired by @MikkaelSekeres with @LeukDocJZ discussing the toughest population out there with TP53 mutated myeloid malignancies @DAVAOnc #BermudaHeme23 (@beatalleukemia)
    Clinical
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    9ms
    Menin inhibition 1 of most promising new class of agents in AML & are clearly active as single agents in R/R AML w/ NPM1mut or KMT2Ar. @EuniceWangMD & Rich Stone present very exciting data w/ Ziftomenib & Revumenib. Can Ziftomenib overcome Menin resistance mut? @DAVAOnc (@LeukDocJZ)
    KMT2A (Lysine Methyltransferase 2A)
    |
    NPM1 mutation
    |
    revumenib (SNDX-5613) • ziftomenib (KO-539)
    9ms
    #regulatory #news ~@Invivoscribe nabs #FDAApproval of mutation assay to patients with FLT3-ITD Positive #AML ~#NecteroMedical receives clearance of IND to initiate trial of Nectero EAST® System ~@Nesa_Medtech receives clearance for fibroid #mapping reviewer application (@MedTechNow_)
    Clinical • FDA event
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation
    9ms
    “I do think this [approval] represents a step forward for patients who have the FLT3 mutation in association with their [AML] over the previous standard, midostaurin [Rydapt],” study author @MikkaelSekeres, MD, said in an interview with CancerNetwork ahead of the approval. https://t.co/nqtM6JI5dz (@CancerNetwrk)
    Clinical • Interview
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation
    |
    Rydapt (midostaurin)
    9ms
    AML ? (@drarpitjoshi)
    9ms
    Are you current on modern therapeutics for patients with #AML? Watch Drs. @Daver_Leukemia, @beatalleukemia, Harry Erba, & Amir Fathi discuss the latest in this CME video, taken from our recent event at #ASCO23. Produced in partnership with @HealthTreeAML. https://t.co/XX5nNy0fKz (@PeerView)
    Clinical • Licensing / partnership • CME • Video
    9ms
    Dr. @aditishasMD at @MDAndersonNews Leukemia giving an excellent talk on the role of STAT3 in AML! it is not everyday that a speaker shows you a pic of their own mitochondria 😲… that’s next level dedication. Sadly I wasn’t fast enough to take a pic of her mitochondria #leusm (@sanamloghavi)
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    9ms
    Venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed AML - @DrHKantarjian #cancer #leukemia #MDAndersoncancercenter #researchers #venetoclax #aml #oncology #drugs #oncodaily https://t.co/xblGnHD2vX (@oncodaily)
    Clinical
    |
    Venclexta (venetoclax)
    9ms
    ICYMI: An #ASCO2023 presentation by @A_Stein_AHC of @cityofhope and colleagues outlined data from a first-in-human study evaluating SAR’579, a trifunctional NK-cell engager, in patients with relapsed or refractory AML. 📚: https://t.co/CLFOCvYiYq (@Blood_Cancers)
    Clinical
    9ms
    In this presentation, hear @rosslevinemd of @MSKCancerCenter discuss how the Tapestri scMRD Assay enhanced MRD detection and simultaneously illuminated the clonal architecture of clonal hematopoiesis/pre-leukemic and leukemic cells surviving AML therapy. https://t.co/XH2LxXec62 (@MissionBio)
    9ms
    3+7 has been gold standard as induction therapy for AML and no regimen has been able to beat it so far But it’s an interesting paper for sure 👏👏 A bigger RCT needed to prove that FLAG is superior (@Satyayadav__)
    Gold standard
    9ms
    Caveat with AML is the complicated role/effects of transplant. But certainly many places where OS should be primary outcome. (@mattjbrunner)
    9ms
    Agree - for AML, SCLC, pancreas, GBM, other aggressive diseases, no need for a surrogate endpoint when using the harder-to-fudge OS is reasonable (@Eddie_Cliff)
    9ms
    Had a patient : AML with t(8,21), 56 year old lady In CR post 1st cycle Azacitidine..... Maybe co-mutations play a role? (@MVijayaran)
    Clinical
    |
    azacitidine
    9ms
    - CML imatinib (& other rarer dz) - EGFR, ALK, ROS, & others in NSCLC - HER2 in breast, gastric Ca - BRAF/MEK in melanoma, thyroid & others - FLT3, IDH in AML (tho trial designs variable) - PSMA in Lu-PSMA @Dr_R_Kurzrock (@Eddie_Cliff)
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
    |
    imatinib
    9ms
    @MDAndersonNews #Leukemia researchers identify the use of venetoclax helps to eliminate the adverse prognostic impact of splicing factor mutations in pts with newly diagnosed #AML | @BloodJournal https://t.co/J2sUGN9nVh #leusm (@DrHKantarjian)
    Clinical
    |
    Venclexta (venetoclax)
    9ms
    ➡️ Check out our latest paper 📃 just out in @BloodJournal analyzing the outcomes of patients with Newly Dx AML having Splicing Factor gene mutations 🧬and the impact of Venetoclax based regimens 💊 @ CDDiNardo @DrHKantarjian @garciamanero @sanamloghavi @MDAndersonNews #leusm https://t.co/zDVTSmk4ci (@jayastuMD)
    Clinical
    |
    Venclexta (venetoclax)
    10ms
    Another perfectly ideal AML journal club with our wild team on "Ten simple rules for getting started on Twitter as a scientist" by @ionicasmeets Inspired by @AaronGoodman33 ✨ (@MariiaBash)
    10ms
    Check out this Seminars and Tumor Board activity from #ASCO23 to hear the latest data on using modern therapeutics for patients with #AcuteMyeloidLeukemia, featuring Drs. @Daver_Leukemia, @beatalleukemia, Erba, & Fathi. Developed with @PeerView! https://t.co/z5R2uYRQro #AML (@HealthTreeAML)
    Clinical
    10ms
    For now yes I would still reccomend for allo-hct if eligible. The interesting question I think is if induction strategy changes in younger aml pts with these mutations. (@hemant_murthy)
    Clinical
    10ms
    CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA WHO DEVELOPED THERAPY-RELATED ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME FOLLOWING AUTOLOGOUS CELL TRANSPLANTATION https://t.co/ZuGML7u2RJ @Fevzi_F_Yalniz @DQBMD @MDAndersonNews #bmtsm #leusm #mmsm (@Transplant_Doc)
    Clinical
    10ms
    CD8+ #Tcell states & clonal architecture are characterized in real-life representative cohort of patients w/ #AML, by @poonamndesai, @HusseinAbbasLab https://t.co/HpxFIxCYzz @patrickreville @Daver_Leukemia @BofeiWang3 @JessRoot1 @DinlerAntunes @mkonople @GreenLymphoLab @DapengHao (@CIR_AACR)
    Clinical
    10ms
    Stay current on modern therapeutics for patients with #AML by watching Drs. @Daver_Leukemia, @beatalleukemia, Harry Erba, & Amir Fathi discuss the latest in this #MedEd CME video, taken from our recent event at #ASCO23. Developed with partners @PeerView! https://t.co/z5R2uYRQro (@HealthTreeAML)
    Clinical • CME • Video
    10ms
    📍subgroup of MDS related gene mutations (ASXL1, SRSF2, SF3B1, STAG2, RUNX1, BCOR, EZH2, U2AF1 and ZRSR2) 👉🏻 OS: CPX-351 38.4 m vs Ida-FLAG 16.3 m #AML19 #AML19trial #MDS #AML @ASH_hematology @BloodAdvances @AML_Hub @jadothm (@DrJCornago)
    RUNX1 (RUNX Family Transcription Factor 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • STAG2 mutation
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation)
    10ms
    What do you need to know about modern therapeutics for patients with #AML? Hear analysis from #ASCO23 experts @Daver_Leukemia, @beatalleukemia, & Drs. Erba, & Fathi, about the latest clinical data! Developed in partnership w/ @PeerView: https://t.co/z5R2uYSogW #MedEd #MedTwitter (@HealthTreeAML)
    Clinical data • Licensing / partnership
    10ms
    Learn about modern therapeutics for patients with #AML from experts @Daver_Leukemia, @beatalleukemia, & Drs. Erba & Fathi, about the latest clinical data! Produced in partnership with @HealthTreeAML: https://t.co/XX5nNy0NA7 #MedEd #MedTwitter #ASCO23 (@PeerView)
    Clinical • Clinical data • Licensing / partnership
    10ms
    Older female - rapidly growing R upper pole AML (6.5 cm) w/ chronic anticoagulation. Limited access to advanced IR care at home in case of spontaneous bleed. Favoring retro SP partial - flank or low anterior approach? @mdstifelman @RoboticsUrology @NYCRoboticTeam @RyanNelson762 (@RoboDocX)
    Metastases
    10ms
    VEN plus AZA for NPM1mut #AML in molecular failure as bridge-to-SCT: safe and effective strategy with MRD neg of rate 82%. @BrunettiLab @cpapayannidis https://t.co/3w9K7iLSK5 #leusm (@BrJHaem)
    NPM1 mutation
    10ms
    ✅ Nice to learn more about the Quantum First trial from Dr. Harry Erba at @_MDEducation AML focus meet. @Daver_Leukemia @jaltmanmd @doctorpemm (@jayastuMD)
    10ms
    🩸 Persistent molecular disease and clonal hematopoiesis are common in AML patients in remission after chemotherapy ➡️ https://t.co/7erYO2QF86 #leusm @dspencerlab @MichaelJSlade (@JCOPO_ASCO)
    Clinical
    10ms
    📣Hear the latest IACH Breaking News Bu-Flu Versus Bu-Cy for AML Patients Undergoing Haplo: a Multi Center Randomized Phase III Trial by Ling Yiwen and Colleagues ⬇️⬇️ https://t.co/JyY70TmFRr @nagler_EBMT @Mohty_EBMT (@TheIACH)
    Clinical
    10ms
    ➡️ The evolving paradigm of therapy in T-cell ALL by @NitinJainMD at US AML/ALL focus meet @_MDEducation ✅ Bcl2/BclXL inhibitors ✅ CD 7 CAR-Ts ✅ LCK inhibition by Dasatinib/Ponatinib https://t.co/btUp5uOKaW (@jayastuMD)
    BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
    |
    dasatinib • Iclusig (ponatinib)
    10ms
    BTF’s updates in Hem/Onc in Houston. Dr. Martha Mims @bcmhouston on MDS/AML. In 2023 so many germline predisposition genes in AML. Should we test all patients with AML for germline alterations ? @btfoundation @binayshah @Dr_R_Kurzrock @SidYadavMD (@VivekSubbiah)
    Clinical
    10ms
    🙌 Awesome to spend time w/my wonderful friend & great collaborator @DoctorGRao today!! 👉 Check out our paper together analyzing the similarities b/t #glioblastoma & #AML| https://t.co/AL6YnyqZSZ | #leusm #LeukemiaStrong #btsm #IDHm #neurosurgery #NeuroOnc 🔬 🧠 🩸 @JNeurooncol (@doctorpemm)
    Surgery
    10ms
    Had a blast in beautiful La Jolla @_MDEducation AML/ALL meeting. Thx for organizing @jaltmanmd. @DrWendyStock and I even survived hiking down a cliff. Cool seeing/meeting @LuskinMarlise @ChenyuLinMD @RyanCassaday @CarrawayHetty @hemedoc @yasminabaza1 @sanamloghavi (@RoloffGreg)
    10ms
    🔉Looking for a great listen? This episode of The HemOnc Pulse features host @chadinabhan speaking with @Dr_AmerZeidan of @yale about AML classification updates, the practical implications of genetic testing, and more. https://t.co/wEyL52NnWL @SocietyofHemOnc (@Blood_Cancers)
    10ms
    Wonderful talk by @mkonople (Dr. Konopleva) summarizing the approach to Ph-like ALL and the impact of TKIs and B-cell directed agents at US AML ALL Focus Meet @_MDEducation https://t.co/UjTvbixMaP (@jayastuMD)
    10ms
    1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation
    |
    gefitinib • imatinib